Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 6, 2012, Pages 891-898

  Zhang, Da ^a   Mita, Monica ^b   Shapiro, Geoffrey I ^c   Poon, Jennifer ^d   Small, Karen ^a   Tzontcheva, Anjela ^a   Kantesaria, Bhavna ^a   Zhu, Yali ^a   Bannerji, Rajat ^e   Statkevich, Paul ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Aprepitant; Cyclin dependent kinase; Dinaciclib; Drug drug interactions; Malignancies

Indexed keywords

APREPITANT; DEXAMETHASONE; DINACICLIB; MK 7965; ONDANSETRON; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TUMOR LYSIS SYNDROME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIEMETICS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BICYCLO COMPOUNDS, HETEROCYCLIC; CROSS-OVER STUDIES; CYCLIN-DEPENDENT KINASES; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LINEAR MODELS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS; ONDANSETRON; PYRIDINIUM COMPOUNDS; TREATMENT FAILURE; VOMITING;

EID: 84871243749     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1967-y     Document Type: Article

References (14)

1. Paruch K, Dwyer MP, Alvarez C, Brown C, Chan T-Y, Doll RJ, Keertikar K, Knutson C, McKittrick B, Rivera J, Rossman R, Tucker G, Fischmann T, Hruza A, Madison V, Nomeir AA, Wang Y, Kirschmeier P, Lees E, Parry D, Sgambellone N, Seghezzi W, Schultz L, Shanahan F, Wiswell D, Xu X, Zhou Q, James RA, Paradkar VM, Park H, Rokosz LR, Stauffer TM, Guzi TJ (2010) Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases. ACS Med Chem Lett 1:204-208
2. Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23:9408-9421
3. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770-1783
4. Bregman DB, Pestell RG, Kidd VJ (2000) Cell cycle regulation and RNA polymerase II. Front Biosci 5:D244-D257
5. Oelgeschlager T (2002) Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 190:160-169
6. Fu W, Ma L, Chu B, Wang X, Bui MM, Gemmer J, Altiok S, Pledger WJ (2011) The cyclin-dependent kinase inhibitor SCH 727965 (dinaciclib) induces the apoptosis of osteosarcoma cells. Mol Cancer Ther 10:1018-1027
7. Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, Seghezzi W, Paruch K, Dwyer MP, Doll R, Nomeir A, Windsor W, Fischmann T, Wang Y, Oft M, Chen T, Kirschmeier P, Lees EM (2010) Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 9:2344-2353
8. Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin BD (2011) Cyclin-dependent kinase inhibitor dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 12: 598-609
9. Mita MM, Mita AC, Moseley J, Poon J, Small KA, Jou Y, Kirschmeier P, Zhang D, Statkevich P, Sankhala KK, Sarantopoulos J, Cleary JM, Chirieac LR, Rodig S, Bannerji R, Shapiro G (2011) A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: final results. J Clin Oncol 29: absrt 3080
10. Merck & Co., Inc. (2011) EMEND (aprepitant). Full Prescribing Information, Whitehouse Station, N.J.
11. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev 9:153-166
12. Nemunaitis J, Saltzman M, Rosenberg MA, Khaira D, Small K, Kirschmeier P, Statkevich P, Abutarif M, Yao S, Bannerji R (2009) A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Clin Oncol 27: absrt 3535
13. Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, Goldberg MR, Murphy G, Gottesdiener KM, Lines CR, Petty KJ, Blum RA (2003) Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 74:150-156
14. Aapro MS, Walko CM (2010) Aprepitant: drug-drug interactions in perspective. Ann Oncol 21:2316-2323